Skip to main content
NCBI home page
Elsevier - PMC COVID-19 Collection logoLink to Elsevier - PMC COVID-19 Collection
. 2016 Feb 26;45(2):162–166. doi: 10.1097/PAT.0b013e32835c76be

Low utilisation of diagnostic microbiology for community acquired pneumonia in regional Victoria

Cameron J Jeremiah *,†,***, Liam M Hannan ‡,§, Rob Baird ‖, Grant Phelps , Brett Knight **
PMCID: PMC7173164  PMID: 23250034

Abstract

Aims

Diagnostic microbiology for community acquired pneumonia (CAP) provides useful information for patient management, infection control and epidemiological surveillance. Newer techniques enhance that information and the time interval for obtaining results. An audit of diagnostic microbiology utilisation, microbiological aetiology, and influence of results on prescribing practices in CAP in a regional Australian hospital setting was performed.

Methods

Clinical, microbiological and outcome data were collected by medical record review of patients discharged from Ballarat Hospital with a diagnosis of CAP over a 12 month period.

Results

Of 184 identified CAP episodes, 47 (25.5%) had no diagnostic microbiology performed. Respiratory virus polymerase chain reaction (PCR) was rarely performed (2.7% of all episodes). Acute serology was frequently requested, however paired acute and convalescent serology was infrequently performed (5/75 testing episodes; 6.7%). CAP severity was not correlated with microbiological investigation intensity. The most common pathogens identified were Streptococcus pneumoniae and Mycoplasma pneumoniae (5.4% and 2.2%, respectively). Diagnostic testing appeared to rarely influence antimicrobial prescribing.

Conclusions

In this setting, diagnostic microbiological tests such as respiratory virus PCR and urinary antigen tests are under-utilised. In contrast, sputum and serological investigations are commonly requested, however rarely influence practice. Interventions to facilitate efficient usage of diagnostic microbiology are required.

Keywords: Community acquired pneumonia, investigation, microbiology

References

  • 1.Charles P.G., Whitby M., Fuller A.J., et al. The etiology of community-acquired pneumonia in Australia: why penicillin plus doxycycline or a macrolide is the most appropriate therapy. Clin Infect Dis. 2008;46:1513–1521. doi: 10.1086/586749. [DOI] [PubMed] [Google Scholar]
  • 2.Charles P.G., Wolfe R., Whitby M., et al. SMART-COP: a tool for predicting the need for intensive respiratory or vasopressor support in community-acquired pneumonia. Clin Infect Dis. 2008;47:375–384. doi: 10.1086/589754. [DOI] [PubMed] [Google Scholar]
  • 3.Mandell L.A., Wunderink R.G., Anzueto A., et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007;44(2):S27–S72. doi: 10.1086/511159. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Lim W.S., Baudouin S.V., George R.C., et al. BTS guidelines for the management of community acquired pneumonia in adults: update 2009. Thorax. 2009;64(3):iii1–iii55. doi: 10.1136/thx.2009.121434. [DOI] [PubMed] [Google Scholar]
  • 5.Lutfiyya M.N., Henley E., Chang L.F., Reyburn S.W. Diagnosis and treatment of community-acquired pneumonia. Am Fam Physician. 2006;73:442–450. [PubMed] [Google Scholar]
  • 6.Fine M.J., Auble T.E., Yealy D.M., et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med. 1997;336:243–250. doi: 10.1056/NEJM199701233360402. [DOI] [PubMed] [Google Scholar]
  • 7.Therapeutic Guidelines Limited. Therapeutic Guidelines: Antibiotic. 13th ed. Melbourne: Therapeutic Guidelines Limited, 2006
  • 8.Druce J., Tran T., Kelly H., et al. Laboratory diagnosis and surveillance of human respiratory viruses by PCR in Victoria, Australia, 2002-2003. J Med Virol. 2005;75:122–129. doi: 10.1002/jmv.20246. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Ishida T., Hashimoto T., Arita M., Ito I., Osawa M. Etiology of community-acquired pneumonia in hospitalized patients: a 3-year prospective study in Japan. Chest. 1998;114:1588–1593. doi: 10.1378/chest.114.6.1588. [DOI] [PubMed] [Google Scholar]
  • 10.Hohenthal U., Vainionpaa R., Meurman O., et al. Aetiological diagnosis of community acquired pneumonia: utility of rapid microbiological methods with respect to disease severity. Scand J Infect Dis. 2008;40:131–138. doi: 10.1080/00365540701534525. [DOI] [PubMed] [Google Scholar]
  • 11.Howard L.S., Sillis M., Pasteur M.C., Kamath A.V., Harrison B.D. Microbiological profile of community-acquired pneumonia in adults over the last 20 years. J Infect. 2005;50:107–113. doi: 10.1016/j.jinf.2004.05.003. [DOI] [PubMed] [Google Scholar]
  • 12.Bartlett J.G. Diagnostic tests for agents of community-acquired pneumonia. Clin Infect Dis. 2011;52(4):S296–S304. doi: 10.1093/cid/cir045. [DOI] [PubMed] [Google Scholar]
  • 13.File T.M. Community-acquired pneumonia. Lancet. 2003;362:1991–2001. doi: 10.1016/S0140-6736(03)15021-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Ewig S., Bauer T., Hasper E., Marklein G., Kubini R., Luderitz B. Value of routine microbial investigation in community-acquired pneumonia treated in a tertiary care center. Respiration. 1996;63:164–169. doi: 10.1159/000196538. [DOI] [PubMed] [Google Scholar]
  • 15.Woodhead M.A., Arrowsmith J., Chamberlain-Webber R., Wooding S., Williams I. The value of routine microbial investigation in community-acquired pneumonia. Respir Med. 1991;85:313–317. doi: 10.1016/s0954-6111(06)80103-4. [DOI] [PubMed] [Google Scholar]
  • 16.Lim I., Shaw D.R., Stanley D.P., Lumb R., McLennan G. A prospective hospital study of the aetiology of community-acquired pneumonia. Med J Aust. 1989;151:87–91. doi: 10.5694/j.1326-5377.1989.tb101168.x. [DOI] [PubMed] [Google Scholar]
  • 17.Charles P.G., Johnson P.D., Grayson M.L. Conundrums in community-acquired pneumonia. Med J Aust. 2006;185:131–132. doi: 10.5694/j.1326-5377.2006.tb00496.x. [DOI] [PubMed] [Google Scholar]
  • 18.Charles P.G., Grayson M.L. Point-of-care tests for lower respiratory tract infections. Med J Aust. 2007;187:36–39. doi: 10.5694/j.1326-5377.2007.tb01112.x. [DOI] [PubMed] [Google Scholar]
  • 19.Charles P.G. Early diagnosis of lower respiratory tract infections (point-of-care tests) Curr Opin Pulm Med. 2008;14:176–182. doi: 10.1097/MCP.0b013e3282f7642f. [DOI] [PubMed] [Google Scholar]
  • 20.Templeton K.E., Scheltinga S.A., van den Eeden W.C., Graffelman A.W., van den Broek P.J., Claas E.C. Improved diagnosis of the etiology of community-acquired pneumonia with real-time polymerase chain reaction. Clin Infect Dis. 2005;41:345–351. doi: 10.1086/431588. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Johansson N., Kalin M., Tiveljung-Lindell A., Giske C.G., Hedlund J. Etiology of community-acquired pneumonia: increased microbiological yield with new diagnostic methods. Clin Infect Dis. 2010;50:202–209. doi: 10.1086/648678. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Kaczmarek M., Owen R., Barr I.G. Annual report of the National Influenza Surveillance Scheme, 2008. Commun Dis Intell. 2010;34:8–22. doi: 10.33321/cdi.2010.34.2. [DOI] [PubMed] [Google Scholar]
  • 23.Mahony J.B. Detection of respiratory viruses by molecular methods. Clin Microbiol Rev. 2008;21:716–747. doi: 10.1128/CMR.00037-07. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Diederen B.M., Van Der Eerden M.M., Vlaspolder F., Boersma W.G., Kluyt-mans J.A., Peeters M.F. Detection of respiratory viruses and Legionella spp. by real-time polymerase chain reaction in patients with community acquired pneumonia. Scand J Infect Dis. 2009;41:45–50. doi: 10.1080/00365540802448799. [DOI] [PubMed] [Google Scholar]
  • 25.Steele T.W. Legionnaires’ disease in South Australia, 1979-1988. Med J Aust. 1989;322(151):5–6. doi: 10.5694/j.1326-5377.1989.tb128470.x. 8. [DOI] [PubMed] [Google Scholar]
  • 26.Barker C.E., Sillis M., Wreghitt T.G. Evaluation of Serodia Myco II particle agglutination test for detecting Mycoplasma pneumoniae antibody: comparison with mu-capture ELISA and indirect immunofluorescence. J Clin Pathol. 1990;43:163–165. doi: 10.1136/jcp.43.2.163. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Therapeutic Guidelines Limited. Therapeutic Guidelines: Antibiotic. 14th ed. Melbourne: Therapeutic Guidelines Limited, 2010
  • 28.Wolff A.M., Taylor S.A., McCabe J.F. Using checklists and reminders in clinical pathways to improve hospital inpatient care. Med J Aust. 2004;181:428–431. doi: 10.5694/j.1326-5377.2004.tb06366.x. [DOI] [PubMed] [Google Scholar]
  • 29.Hauck L.D., Adler L.M., Mulla Z.D. Clinical pathway care improves outcomes among patients hospitalized for community-acquired pneumonia. Ann Epidemiol. 2004;14:669–675. doi: 10.1016/j.annepidem.2004.01.003. [DOI] [PubMed] [Google Scholar]
  • 30.Korman T.M., Fuller A., Ibrahim J., Kaye D., Bergin P. Fatal Legionella longbeachae infection following heart transplantation. Eur J Clin Microbiol Infect Dis. 1998;17:53–55. doi: 10.1007/BF01584366. [DOI] [PubMed] [Google Scholar]

Articles from Pathology are provided here courtesy of Elsevier

RESOURCES